Rockwell Medical Technologies (NASDAQ: RMTI) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $13.35 million.

Q3 2017 Financial Highlights

• Sales were $14.6 million, an increase of 14.1% or $1.8 million over third quarter of 2016.
• Gross profit was $1.1 million, compared to $1.6 million in Q3 2016.
• SG&A expense was $4.8 million, compared $5.1 million in Q3 2016.
• R&D expense was $1.3 million, same as Q3 2016.
• Net loss was $5.1 million or ($0.10) per share compared to a $4.6 million loss or ($0.09) per share in Q3 2016.
• Cash and investments were $38.9 million as of September 30, 2017.
• Net working capital was $53.6 million as of September 30, 2017 compared to $56.1 million at June 30, 2017.

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.